Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Aytu Biopharma (AYTU) over the last 15 years, with Sep 2025 value amounting to $2.3 million.

  • Aytu Biopharma's Cash from Financing Activities rose 152.03% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 606.17%. This contributed to the annual value of $15.4 million for FY2025, which is 1323.69% up from last year.
  • As of Q3 2025, Aytu Biopharma's Cash from Financing Activities stood at $2.3 million, which was down 82.33% from $13.0 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Cash from Financing Activities peaked at $13.6 million during Q3 2022, and registered a low of -$6.4 million during Q1 2021.
  • Over the past 3 years, Aytu Biopharma's median Cash from Financing Activities value was $911,000 (recorded in 2024), while the average stood at $1.2 million.
  • As far as peak fluctuations go, Aytu Biopharma's Cash from Financing Activities tumbled by 2,090.48% in 2024, and later skyrocketed by 1,116.57% in 2025.
  • Over the past 5 years, Aytu Biopharma's Cash from Financing Activities (Quarterly) stood at $6.6 million in 2021, then plummeted by 128.30% to -$1.9 million in 2022, then skyrocketed by 93.24% to -$126,000 in 2023, then plummeted by 2,090.48% to -$2.8 million in 2024, then spiked by 152.03% to $2.3 million in 2025.
  • Its Cash from Financing Activities was $2.3 million in Q3 2025, compared to $13.0 million in Q2 2025 and $4.3 million in Q1 2025.